BERTILIMUMAB

BERTILIMUMAB

Supported by 1,500 peer-reviewed studies, Bertilimumab is a first-in-class antibody which targets and lowers eotaxin-1 levels. It is being studied to see if it will improve outcomes in patients with autoimmune diseases that do not have therapies or the therapies have severe limitations, such as Bullous Pemphigoid and Crohn's & Colitis Read More 

Latest News

EVENT February 24, 2017

IMNP Dermatology (Bullous Pemphigoid and Atopic Dermatitis) Educational Symposium | Read more 

 

EVENT February 24, 2017

Immune is Celebrating Rare Disease Day 2017, An Important Day for Bullous Pemphigoid Patients Worldwide | Read more 

 

NEWS February 23, 2017

Immune CEO Daniel Teper answers Cytovia questions in an interview with Jane King | Read more 

 

See All News 

Upcoming Events

February 28, 2017

Immune is Celebrating Rare Disease Day 2017, An Important Day for Bullous Pemphigoid Patients Worldwide
http://www.rarediseaseday.org/
Event Details 

 

March 2, 2017

IMNP Dermatology (Bullous Pemphigoid and Atopic Dermatitis) Educational Symposium
Embassy Suites Orlando International Drive/Convention Center 8978 International Drive, Orlando, FL 32819
Event Details 

 

See All Events